Key result
Tyramide Signal Amplification increases detectable transmural connexin-43 staining ~42% over antibody alone.
Why the study?
Previous mapping studies of connexin-43 distribution across the ventricular wall showed variable findings potentially due to histochemical detection problems and low protein expression levels.
Does Tyramide Signal Amplification improve the immunohistochemical detection of connexin-43 in rabbit hearts compared to antibody alone?
Does Tyramide Signal Amplification improve the immunohistochemical detection of connexin-43 in rabbit hearts compared to antibody alone?
Tyramide signal amplification significantly enhances the immunohistochemical detection of connexin-43 gap junctions in the mammalian heart.
Enhances connexin-43 detection sensitivity in rabbit hearts; leaves open translation to human tissue and clinical use.
Previous mapping studies examinig the distribution and pattern of staining for connexin-43 expression (the major ventricular gap junction protein) across the ventricular wall have yielded variable findings. The aim of this study was to determine if variations in the distribution of connexin-43 were due to histochemical detection problems, i.e. cross-linking of antigenic sites as a consequence of aldehyde fixation and/or due to low levels of protein expression within the epicardial or endocardial regions of the heart. Immunoperoxidase staining of connexin-43 using the ABC method was carried out in crosssections of rabbit hearts at the level of the papillary muscle. The following treatments were examined: the antibody (Ab) only, Ab with 1/2 Tyramide Signal Amplification (TSA) or full TSA; antibody with microwave antigen retrieval (AR); Ab + 1/2 TSA + AR and finally Ab + TSA + AR. Under light microscopy and using computerized image analysis the percentages of ventricular cross-sectional transmural staining for the different treatment groups were calculated: Ab amounted to only 55%; Ab + 1/2 TSA 63%; Ab + TSA 78%; Ab + AR 72%; Ab + AR + 1/2 TSA 72% and Ab + AR + TSA 88%. The percentages of transumural connexin-43 staining in both TSA + Ab and Ab + TSA + AR groups when compared to Ab only were significantly greater p < 0.01. The antigenic cross-linking due to aldehyde fixation and low levels expression of connexin-43 are contributing factors that influence the immunohistochemical detection of connexin-43 in the mammalian heart. Methodological enhancement for the detection of connexin-43 in this study was derived primarily from amplification of low background levels of connexin-43 being expressed using the TSA protocol. This is supported by the significant differences encountered when TSA was utilized in the protocol and compared with antibody treatment only.
No takes yet. Share an insight, caveat, or question.
McLachlan et al. (2003) studied this question. Tyramide Signal Amplification (TSA) vs. Antibody only was evaluated on Percentages of ventricular cross-sectional transmural staining for connexin-43 (p=< 0.01). Tyramide Signal Amplification significantly increased the detectable percentage of transmural connexin-43 staining in rabbit hearts compared to antibody alone (78% vs 55%, p<0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: